Best response rates
| Best response . | Rd-R (n = 101) . | Rd (n = 98) . | All patients (n = 199) . |
|---|---|---|---|
| ORR | 79 (78) | 67 (68) | 146 (73) |
| ≥VGPR | 52 (51) | 38 (39) | 90 (45) |
| sCR | 4 (4) | — | 4 (2) |
| CR | 1 (1) | 1 (1) | 2 (1) |
| nCR* | 19 (19) | 15 (15) | 34 (17) |
| VGPR | 28 (28) | 22 (22) | 50 (25) |
| PR | 27 (27) | 29 (30) | 56 (28) |
| SD | 12 (12) | 17 (17) | 29 (15) |
| PD | — | 6 (6) | 6 (3) |
| Not evaluable | 10 (10) | 8 (8) | 18 (9) |
| Best response . | Rd-R (n = 101) . | Rd (n = 98) . | All patients (n = 199) . |
|---|---|---|---|
| ORR | 79 (78) | 67 (68) | 146 (73) |
| ≥VGPR | 52 (51) | 38 (39) | 90 (45) |
| sCR | 4 (4) | — | 4 (2) |
| CR | 1 (1) | 1 (1) | 2 (1) |
| nCR* | 19 (19) | 15 (15) | 34 (17) |
| VGPR | 28 (28) | 22 (22) | 50 (25) |
| PR | 27 (27) | 29 (30) | 56 (28) |
| SD | 12 (12) | 17 (17) | 29 (15) |
| PD | — | 6 (6) | 6 (3) |
| Not evaluable | 10 (10) | 8 (8) | 18 (9) |
Data presented as n (%).
CR, complete response; nCR, near complete response; ORR, overall response rate; PR, partial response; sCR, stringent complete response; SD, stable disease; VGPR, very good partial response.
Immunofixation negative; bone marrow examination not performed.